Video B-Roll via satellite - Health Canada approves new treatment for HIV

    CELSENTRI(TM) (maraviroc) Tablets First in a New Class of Oral HIV
    Medicines in More than a Decade

    TORONTO, Oct. 15 /CNW/ - The following B-Roll is available at the listed
times and co-ordinates:

    DATE OF FEEDS:     Monday, October 15, 2007

    TIME OF FEEDS:     10:00 - 10:30 am ET
                       2:00 - 2:30 pm ET

    CO-ORDINATES:      Anik F2 C
                       Transponder 7B
                       Audio subcarrier 6.2 and 6.8
                       Downlink frequency 3980 vertical

    TOC                CFA TX 1

    On-Demand Coordinates / URL available from 10:00 a.m. ET onwards, Monday,
October 15th 2007

    CNW Broadcast On-Demand provides free, secure and easy-to-use broadcast
quality material direct from our website to accredited journalists worldwide.
Please contact if you do not already have log-in rights.

    STORY SUMMARY: CELSENTRI is the first in a new class of oral HIV medicine
in more than 10 years. CELSENTRI works differently than other HIV treatments;
it blocks entry of HIV into white blood cells, reducing the level of HIV in
the system of people with HIV.
    CELSENTRI is the first in a class of drugs known as CCR5 antagonists,
which block a co-receptor which is the virus' main entry route into the body's
immune cells or CD4+ cells. CELSENTRI stops the R5 virus on the outside
surface of the cell before it enters, rather than fighting the virus inside
the cell as do all other classes of oral HIV medicines.
    The development of CELSENTRI goes back to 1996 when a group of people
were found to have a gene mutation that left them immune to HIV. The virus was
not able to enter their immune cells. Pfizer scientists discovered the
compound which was to become CELSENTRI.

    The B-roll will feature:

    Dr. Sharon Walmsley, MSc, MD, FRCPC Department of Medicine, University of
    Toronto (English)
    Dr. Cécile Tremblay, FRCPC Directrice UHRESS du CHUM, microbiologiste
    infectiologue (French)
    Dr. Manos Perros, Executive Director, Head of Antiviral Research, Pfizer
    Global Research and Development

Fleishman-Hillard, at 416-645-3641 or Julie-Catherine Racine, Pfizer Canada,
at 514-693-4602. For technical information DURING the feed, please call

    As with all CNW Broadcast feeds, this release is offered for your free
and unrestricted news use. Comments regarding the content and quality are

For further information:

For further information: CNW BROADCAST, TORONTO (416) 863-5615

Organization Profile

CNW Video Services

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890